Methylphenidate — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for ADHD (Attention Deficit Hyperactivity Disorder)

• Amphetamine Salts
• Atomoxetine
• Clonidine
• Guanfacine

Other medications in Mental Health

• Mirtazapine
• Molindone
• Naltrexone
• Nefazodone
• Nortriptyline
• Olanzapine
• Paliperidone
• Paroxetine

About Methylphenidate

Methylphenidate is a widely prescribed medication primarily used to manage conditions like Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. Understanding its benefits and how to access it affordably is key to consistent treatment. At TheDrugClub, we're dedicated to making essential medications more accessible, helping members save significantly, often bringing their methylphenidate co-pay down to $0.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Methylphenidate is approved for (FDA label)

Methylphenidate transdermal system is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Source: Read the full FDA label on DailyMed. Label effective date: October 7, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Methylphenidate (FDA label)

WARNING: ABUSE, MISUSE, AND ADDICTION Methylphenidate transdermal system has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate transdermal system, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing methylphenidate transdermal system, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout methylphenidate transdermal system treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) and Drug Abuse and Dependence (9.2) ] . WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning Methylphenidate transdermal system has high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate transdermal system, can result in overdose and death ( 5.1 , 9.2 , 10 ): • Before prescribing methylphenidate transdermal system, assess each patient’s risk for abuse, misuse, and addiction. • Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.

Source: FDA prescribing information (DailyMed). Set ID: 1643b6a5-80da-4d4f-8c5f-feb907875702. SPL document ID: c5b3220c-d8cc-42a7-a0e8-3cc1ccc3d535. Label effective date: October 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Methylphenidate (FDA label)

Four dosage strengths of Methylphenidate Transdermal System are available as 10 mg/9 hrs (1.1 mg/hr), 15 mg/9 hrs (1.6 mg/hr), 20 mg/9 hrs (2.2 mg/hr) or 30 mg/9 hrs (3.3 mg/hr) of methylphenidate. • Each dosage form is a translucent rectangular transdermal system with rounded corners consisting of a matte backing film randomly printed with “Methylphenidate Transdermal System” and the “mg/hr” strength in white ink, an adhesive layer and a clear to slightly hazy oversized release liner that is slit. Each transdermal system is overlaid with an additional clear to slightly hazy oversized release liner and is contained in a square, flat pouch that is imprinted with lot number and expiration date.

Source: FDA prescribing information (DailyMed). Set ID: 1643b6a5-80da-4d4f-8c5f-feb907875702. SPL document ID: c5b3220c-d8cc-42a7-a0e8-3cc1ccc3d535. Label effective date: October 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Methylphenidate (FDA label)

Detailed information on serious and adverse reactions of particular importance is provided in the Boxed Warning and Warnings and Precautions (5) sections: • Abuse, Misuse, and Addiction [see Boxed Warning ] • Hypersensitivity to Methylphenidate [see Contraindications (4.1) ] • Monoamine Oxidase Inhibitors [see Contraindications (4.2) and Drug Interactions (7.1) ] • Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions (5.2) ] • Increased Blood Pressure and Heart Rate [see Warnings and Precautions (5.3) ] • Psychiatric Adverse Reactions [see Warnings and Precautions (5.4) ] • Seizures [see Warnings and Precautions (5.5) ] • Priapism [see Warnings and Precautions (5.6) ] • Peripheral Vasculopathy [see Warnings and Precautions (5.7) ] • Long-Term Suppression of Growth in Pediatric Patients [see Warnings and Precautions (5.8) ] • Chemical Leukoderma [see Warnings and Precautions (5.9) ] • Contact Sensitization [see Warnings and Precautions (5.10) ] • External Heat [see Warnings and Precautions (5.11) ] • Hematologic Monitoring [see Warnings and Precautions (5.12) ] • Acute Angle Closure Glaucoma [see Warnings and Precautions (5.13) ] • Increased Intraocular Pressure and Glaucoma [see Warnings and Precautions (5.14) ] • Motor and Verbal Tics, and Worsening of Tourette’s Syndrome [see Warnings and Precautions (5.15) ] • Pediatric patients (ages 6 to 12 years): The most commonly (≥ 5% and twice the rate of placebo) reported adverse reactions in pediatric patients ages 6 to 12 years included appetite decreased, insomnia, nausea, vomiting, weight decreased, tic, affect lability, and anorexia. ( 6.1 ) • Pediatric patients (ages 13 to 17 years): The most commonly (≥ 5% and twice the rate of placebo) reported adverse reactions in pediatric patients ages 13 to 17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia.

Source: FDA prescribing information (DailyMed). Set ID: 1643b6a5-80da-4d4f-8c5f-feb907875702. SPL document ID: c5b3220c-d8cc-42a7-a0e8-3cc1ccc3d535. Label effective date: October 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Methylphenidate (FDA label)

• Known hypersensitivity to methylphenidate ( 4.1 ) • Patients currently using or within 2 weeks of using an MAO inhibitor ( 4.2 ) 4.1 Hypersensitivity to Methylphenidate Methylphenidate transdermal system is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product (fluoropolymer-coated polyester, hydrophobic colloidal silica, mineral oil, polyester/ethylene vinyl acetate laminate film backing, polyisobutylene adhesive and white ink). The white ink contains acrylic polymers, polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, sodium dioctyl sulfosuccinate and titanium dioxide [see Description (11) ] . 4.2 Monoamine Oxidase Inhibitors Methylphenidate transdermal system is contraindicated during treatment with monoamine oxidase inhibitors, and within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor (hypertensive crises may result).

Source: FDA prescribing information (DailyMed). Set ID: 1643b6a5-80da-4d4f-8c5f-feb907875702. SPL document ID: c5b3220c-d8cc-42a7-a0e8-3cc1ccc3d535. Label effective date: October 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Methylphenidate (FDA label)

• Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. ( 5.2 ) • Increased Blood Pressure and Heart Rate: Monitor blood pressure and pulse. ( 5.3 ) • Psychiatric Adverse Reactions: Prior to initiating methylphenidate transdermal system, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing methylphenidate transdermal system. ( 5.4 ) • Seizures: Stimulants may lower the convulsive threshold. Discontinue in the presence of seizures. ( 5.5 ) • Priapism: If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. ( 5.6 ) • Peripheral Vasculopathy, including Raynaud’s phenomenon: Careful observation for digital changes is necessary during methylphenidate transdermal system treatment.

Source: FDA prescribing information (DailyMed). Set ID: 1643b6a5-80da-4d4f-8c5f-feb907875702. SPL document ID: c5b3220c-d8cc-42a7-a0e8-3cc1ccc3d535. Label effective date: October 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Methylphenidate (FDA label)

• Antihypertensive Drugs: Monitor blood pressure. Adjust dosage of antihypertensive drug as needed. ( 7.2 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) Concomitant use of MAOIs and CNS stimulants, including methylphenidate transdermal system, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure [see Contraindications (4.2) ] . Concomitant use of methylphenidate transdermal system with MAOIs or within 14 days after discontinuing MAOI treatment is contraindicated. 7.2 Antihypertensive Drugs Methylphenidate may decrease the effectiveness of drugs used to treat hypertension.

Source: FDA prescribing information (DailyMed). Set ID: 1643b6a5-80da-4d4f-8c5f-feb907875702. SPL document ID: c5b3220c-d8cc-42a7-a0e8-3cc1ccc3d535. Label effective date: October 7, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.